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Abstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. 
Osteoporotic fractures cause disability and disﬁ  gurement and threaten patients’ mobility, inde-
pendence, and survival. Care for incident fractures in this age group must go beyond orthopedic 
repair, to assessment and treatment of the underlying bone fragility. Fracture risk can be reduced 
by vitamin D and calcium supplementation along with antiresorptive drug treatment. First-line 
osteoporosis pharmacotherapy employs nitrogen-containing bisphosphonates. The inconvenience 
of daily oral treatment has motivated development of weekly, monthly, and intermittent oral 
regimens, as well as quarterly and yearly intravenous (iv) regimens. Ibandronate is the ﬁ  rst 
bisphosphonate to have shown direct anti-fracture efﬁ  cacy with a non-daily regimen; it was 
approved for once-monthly oral dosing in 2005 and for quarterly iv dosing in 2006. Intermit-
tent oral risedronate and yearly iv zoledronic acid were approved in 2007. Newly available 
regimens with extended dosing intervals reduce the inconvenience of bisphosphonate therapy 
and provide patients with a range of options from which to select a maximally sustainable 
course of treatment. This review discusses the development, efﬁ  cacy, safety, and tolerability 
of extended-interval bisphosphonate regimens and examines their potential to improve patient 
acceptance and long-term success of osteoporosis treatment.
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Background
Osteoporosis – a progressive loss of bone strength and quality that multiplies fracture 
risk – is a common and underrecognized hazard to postmenopausal women. Its preva-
lence among US women ranges from 26% at age 65 years and older to over 50% at age 
85 years and older (US Department of Health and Human Services 2004), reﬂ  ecting 
an altered balance of bone turnover that begins immediately upon menopause and 
increases steadily with age (Garnero et al 1996b). Fortunately, osteoporosis is eminently 
preventable and treatable. Lifelong attention to nutrition and exercise, bone density 
monitoring after menopause, and appropriate treatment of diagnosed osteoporosis can 
reduce the burden of disability, cost, and mortality.
Bone densitometry by dual-energy X-ray absorptiometry (DXA), which measures 
bone mineral density (BMD), is the canonical method for diagnosing osteoporosis 
(Briot and Roux 2005). The relationship between low BMD and fracture is stronger 
than the relationship between cholesterol and heart attacks (US Department of Health 
and Human Services 2004). Judicious BMD testing should be considered in at-risk 
postmenopausal women, in younger women with multiple risk factors, and in all 
patients who present with fragility fractures or take medications that can reduce BMD 
(US Department of Health and Human Services 2004). At a minimum, BMD screening 
of all men and women should be considered at 65 years of age.Clinical Interventions in Aging 2008:3(4) 612
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The World Health Organization (WHO) defines 
osteoporosis as a BMD T-score of  2.5 standard deviations 
below the gender-speciﬁ  c young adult mean, as measured by 
DXA (World Health Organization 1994). However, total frac-
ture risk reﬂ  ects both BMD-dependent and BMD-independent 
risk factors (Kanis et al 2007). The 2008 National Osteopo-
rosis Foundation practice guidelines (National Osteoporosis 
Foundation 2008) (Table 1) utilize FRAX™, the new WHO 
absolute fracture risk algorithm (Kanis 2008), which takes 
into account BMD, age, smoking, alcohol intake, personal or 
parental history of fracture, body mass index, corticosteroid 
use, and rheumatoid arthritis to predict individual patients’ 
10-year probability of sustaining osteoporotic fractures.
Osteoporotic fractures, with an estimated annual inci-
dence of 2 million among US citizens aged 50 years or older 
(Burge et al 2007), have severe physical, economic, and 
psychosocial consequences. Direct physical consequences 
include temporary or permanent disability and disﬁ  gurement. 
If fracture sufferers become bedfast, indirect consequences 
such as decubitus ulcers, pneumonia, and urinary tract 
infections may result (US Department of Health and Human 
Services 2004). Mortality risk increases 2.8- to 4-fold during 
the ﬁ  rst 3 months after a hip fracture (US Department of Health 
and Human Services 2004). In the US, 500,000 hospitaliza-
tions, 800,000 emergency room visits, and 180,000 nursing 
home placements yearly are attributable to osteoporotic 
fractures (US Department of Health and Human Services 
2004), requiring annual direct care expenditures estimated 
at US$16.9 billion and total costs exceeding US$19 billion 
(2005 dollars) (Burge et al 2007). A 2007 case-control study 
reported incremental costs of US$4,007 per Medicaid ben-
eﬁ  ciary or US$5,370 per Medicare beneﬁ  ciary during the 
ﬁ  rst post-fracture year (Rousculp et al 2007).
A particularly distressing cost of osteoporosis to elderly 
patients and their families is potential loss of independence. 
Fracture sufferers often lose more mobility through fear than 
they lose to the direct effects of injury. This effect can synergize 
with the direct effects of fractures on mobility and morbidity 
to cause self-perpetuating inactivity, social isolation, and func-
tional dependence, often culminating in institutionalization 
(US Department of Health and Human Services 2004).
Calcium and vitamin D supplementation are essential 
in the prevention and therapy of osteoporosis and have 
been used in all of the major trials of osteoporosis drugs 
(Sunyecz and Weisman 2005). The US Institute of Medicine’s 
estimated adequate intakes for adults aged  50 years are 
1200 g calcium (with  700 mg preferably derived from diet) 
and 800–1000 units vitamin D (Standing Committee on the 
Scientiﬁ  c Evaluation of Dietary Reference Intakes 1997). 
Calcium supplementation (1000 mg/day) prevents BMD 
loss and may reduce vertebral fractures in postmenopausal 
women, as shown in a meta-analysis by the Agency for Health 
Research and Quality (MacLean et al 2008). Vitamin D 
(700–800 international units/day) with or without calcium 
reduced hip and non-vertebral fractures versus placebo in 
another meta-analysis (Bischoff-Ferrari et al 2005). 
Table 1 Diagnostic categories of BMD and appropriate clinical responses (World Health Organization 1994; Healy 1998; Hodgson et al 
2001; Kanis 2008)
Classiﬁ  cation T -score Clinical response
Normal Exceeding −1 • Reassure
•   Encourage adequate calcium and vitamin D intake and 
weight-bearing exercise
Osteopenia   −1 to   −2.5 •  Maintain nutrition and exercise
•   Assess risk factors (personal or family history of fracture, 
smoking, alcohol intake 3 units/day, low body weight, 
corticosteroid use, rheumatoid arthritis)
•   Consider bisphosphonate treatment if 10-year hip fracture 
probability is  3% or probability of any major osteoporotic 
fracture is  20% by regionally appropriate WHO model at 
http://www.shef.ac.uk/FRAX/index.htm
Osteoporosis −2.5 or less •  Maintain nutrition and exercise
•  Assess and reduce risk of falls
•  Institute bisphosphonate therapy
Severe osteoporosis −2.5 or less and fragility fracture •   Maintain nutrition and supervised/adapted exercise (avoiding 
spinal twists, forward bends, and high-impact activities)
•  Assess and reduce risk of falls
•  Continue bisphosphonate therapyClinical Interventions in Aging 2008:3(4) 613
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In addition to lifelong preventive nutrition and weight-bearing 
exercise, antiresorptive treatment with nitrogen-containing 
bisphosphonates has become standard ﬁ  rst-line therapy for 
postmenopausal osteoporosis. Timely diagnosis and effective 
treatment of osteoporosis can reduce the incidence of frac-
tures and their multifaceted individual and societal costs.
Objective
Bisphosphonates have become the standard first-line 
treatment for postmenopausal osteoporosis. This paper will 
trace the evolution of bisphosphonate therapies from daily to 
monthly or less frequent dosing regimens, outline evidence 
on efﬁ  cacy, safety, and tolerability, and examine their poten-
tial to improve patient acceptance and clinical outcomes of 
osteoporosis treatment.
Bisphosphonate pharmacology
and dosing frequencies
Two features of bisphosphonate structure determine bio-
logical activity (Figure 1). The arrangement of 2 phosphate 
groups bound to a geminal carbon (rather than an oxygen 
as in pyrophosphate) creates a non-hydrolyzable pyrophos-
phate analog (Rogers et al 2000), and the R1 and R2 groups 
occupying the carbon’s other bonds mediate high-afﬁ  nity 
calcium chelation. Thus, bisphosphonates are readily and 
tenaciously incorporated into bone mineral surfaces, where 
they are consumed by osteoclasts at remodeling sites.
Within osteoclasts, non-nitrogen-containing bisphospho-
nates are metabolized to apoptosis-inducing compounds. 
Nitrogen-containing bisphosphonates (the focus of this 
review) inhibit protein prenylation by farnesyl pyrophosphate 
synthase and thus disrupt the cellular physiology of resorp-
tion (Dunford et al 2001). Inhibitory potency, determined by 
the R2 group, is increased by tertiary nitrogen (as in iban-
dronate) or a heterocyclic ring (as in risedronate and zole-
dronic acid) (Dunford et al 2001). An upstream metabolite 
that accumulates during prenylation inhibition, isopentenyl 
pyrophosphate, is further metabolized to an apoptosis-
inducing product (Monkkonen et al 2007). Although osteo-
clast apoptosis is not essential for antiresorptive activity of 
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nitrogen-containing bisphosphonates, it plays a contributory 
role (Russell et al 2008).
Suppression of bone turnover by nitrogen-containing 
bisphosphonates manifests in decreased serum and urine 
levels of bone turnover markers (Table 2). The bone collagen 
breakdown products cross-linked C-telopeptide (CTX) or 
N-telopeptide (NTX) are often used in clinical follow-up. 
The rate and magnitude of their decreases in response to 
treatment depend on bisphosphonate potency, dose, route, 
and interval.
Evolution of dosing regimens
Nitrogen-containing bisphosphonates have become the 
standard of care for osteoporosis. US approval dates for 
currently available bisphosphonate regimens are shown in 
Figure 2. Oral bisphosphonate dosing (daily, weekly, or 
monthly) is popular for ﬁ  rst-line treatment in the outpatient 
setting. Intravenous (iv) regimens (quarterly or yearly), are 
newer options available to patients with postmenopausal 
osteoporosis. Intravenous bisphosphonates are particularly 
helpful for those who are bedfast or have esophageal disor-
ders, cognitive problems, or other dosing challenges.
Alendronate, risedronate, and ibandronate all were initially 
approved by the Food and Drug Administration (FDA) for 
daily oral dosing, supported by trials with direct anti-frac-
ture efﬁ  cacy endpoints (Black et al 1996; Harris et al 1999; 
McClung et al 2001; Chesnut et al 2004). The burdensome 
dosing requirements needed for gastrointestinal (GI) protection 
with daily oral bisphosphonates have motivated development 
of less frequent oral regimens. Weekly dosing is made pos-
sible by the long half-life of bone-bound bisphosphonates, 
which remain at resorption sites longer than the 2-week 
lifespan of individual osteoclasts (Bone et al 2000). Weekly 
oral alendronate and risedronate achieved approval based on 
comparisons with the respective daily regimens (Schnitzer 
et al 2000; Brown et al 2002). Weekly oral ibandronate has 
also shown non-inferior efﬁ  cacy to the daily regimen (Cooper 
et al 2003) but has not been marketed. These weekly regimens, 
with 7 times the daily oral dose, maintain continuous reduction 
of bone turnover markers (Papapoulos and Schimmer 2007).
Bisphosphonate pharmacology also makes possible 
monthly, intermittent, quarterly, or yearly dosing. In the quest 
for improved adherence and persistence, these extended-
interval regimens provide important lifestyle-friendly options. 
Monthly oral ibandronate, the ﬁ  rst approved monthly bisphos-
phonate regimen, was supported by comparison trials with the 
daily regimen and has been in use since 2005 (Miller et al 2005; 
Reginster et al 2006). Pharmacodynamically, monthly oral 
ibandronate utilizes a non-linear dose increase versus the daily 
oral regimen (150 mg/month vs 2.5 mg/day), which more than 
doubles annual cumulative skeletal exposure (ACE; 10.8 mg 
with monthly vs 5.5 mg with daily oral treatment) (Zaidi et al 
2007). Increased ACE maintains efﬁ  cacy during the interdose 
periods of extended-interval regimens (Zaidi et al 2007). Bone 
turnover markers show marked suppression within 3 days 
after a 150 mg/month oral ibandronate dose and reach a nadir 
by 7 days postdose (Silverman et al 2007a); although marker 
levels gradually increase during the interdose period, they 
remain throughout the month within the premenopausal range 
required for efﬁ  cacy (Papapoulos and Schimmer 2007).
An intermittent oral risedronate regimen (2 consecu-
tive days monthly) was approved in April 2007 (Delmas et al 
2008a), and a once-monthly risedronate dosing regimen 
was approved in April 2008 (Delmas et al 2008b). These 
risedronate regimens provide 30 times the daily oral dose. 
Comparison to daily oral risedronate shows that they achieve 
similar bone turnover marker suppression and BMD increases 
(Delmas et al 2007a; Delmas et al 2007b).
Table 2 Biomarkers of bone turnover (After Leeming et al 2006)
Processes Biomarkers Descriptions
Bone resorption Bone type I collagen N-telopeptide Collagen breakdown product generated by osteoclast 
cathepsin K
Bone type I collagen C-telopeptide Collagen breakdown product generated by osteoclast 
cathepsin K
Deoxypyridinoline Collagen breakdown product; remnant of cross-links 
of collagen polypeptides
Tartrate-resistant alkaline phosphatase Osteoclastic enzyme; may indicate osteoclast number
Bone formation Bone-speciﬁ  c alkaline phosphatase Osteoblastic enzyme involved in bone mineralization
Osteocalcin Major non-collagen protein of bone
Aminoterminal propeptide of type 1 procollagen Byproduct of mature collagen formation
Carboxyterminal propeptide of type 1 procollagen Byproduct of mature collagen formationClinical Interventions in Aging 2008:3(4) 615
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Intravenous bisphosphonate regimens decouple 
bisphosphonate therapy from stringent oral dosing require-
ments, providing alternative options for any postmenopausal 
osteoporosis patients and extending the beneﬁ  ts of bisphos-
phonates to patients unable to take them orally. Quarterly iv 
ibandronate (3 mg/3 month), approved in 2006, has shown 
efﬁ  cacy in postmenopausal osteoporosis with a similar safety 
proﬁ  le to the monthly oral regimen (Delmas et al 2006). The 
lower-dose iv ibandronate regimens investigated during drug 
development did not achieve clinical efﬁ  cacy because bone 
turnover returned toward untreated levels during the interdose 
periods (Adami et al 2004; Recker et al 2004). The approved 
3 mg/3 month iv dose provides the highest annual cumulative 
skeletal exposure of approved ibandronate regimens (12 mg) 
(Zaidi et al 2007), resulting in superior efﬁ  cacy to daily oral 
ibandronate (Eisman et al 2008).
Zoledronic acid was originally developed as a high-
potency agent for single-dose iv infusion to treat hypercal-
cemia (Major 2002) and skeletal complications (Perry and 
Figgitt 2004) of malignancy. Suppression of bone turnover in 
osteopenic or osteoporotic postmenopausal women infused 
with 5 mg zoledronic acid was more rapid and pronounced 
than in those receiving 70 mg/week oral alendronate (Saag 
et al 2007); further investigations in postmenopausal osteo-
porosis led to the 2007 approval of a yearly iv zoledronic acid 
regimen (5 mg/year) for this indication (Black et al 2007).
Bisphosphonate efﬁ  cacy, safety, 
and tolerability
Key randomized trials evaluating nitrogen-containing 
bisphosphonates individually and comparatively are 
summarized in Table 3; their ﬁ  ndings on efﬁ  cacy, safety, 
and tolerability are described below.
Efﬁ  cacy studies
Pivotal trials supporting approval of daily oral nitrogen-
containing bisphosphonate regimens utilized fracture-
based primary endpoints. After these daily regimens 
attained approval, “bridging trials” supporting less frequent 
dosing regimens were designed to show non-inferiority or 
equivalence to daily regimens by means of surrogate BMD 
endpoints.
Daily oral regimens
The Fracture Intervention Trial (FIT) evaluated oral 
alendronate (5 mg/day for the ﬁ  rst 2 years; 10 mg/day 
thereafter) vs placebo in women with (Black et al 1996) or 
without (Cummings et al 1998) baseline vertebral fractures. 
Alendronate reduced the relative risk of new vertebral frac-
tures by roughly 50% in the group with prevalent vertebral 
fractures (Black et al 1996); hip and wrist fracture risks also 
decreased by roughly 50%, and that of non-vertebral fractures 
by 20% (Table 2). In the group without baseline vertebral 
fractures (Cummings et al 1998), new vertebral fracture risk 
decreased by approximately 45%; non-vertebral fracture 
effects depended on baseline BMD (Table 2).
In the FIT Long-term EXtension study (FLEX) (Bone 
et al 2004), FIT participants who received alendronate 
for 5 years were re-randomized to continue alendronate 
(5 or 10 mg/day) or to switch to placebo for 5 additional 
years. In the group who received alendronate for a total of 
10 years, BMD increased at multiple sites compared with 
baseline; lumbar spine BMD continued increasing throughout 
1995 2000 2002 2004 2006 2008
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Figure 2 Timeline of Food and Drug Administration approvals of different bisphosphonate regimens.Clinical Interventions in Aging 2008:3(4) 616
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Monthly, quarterly and yearly bisphosphonates
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Sunyecz
treatment (Table 2); the 70 mg/week oral alendronate regimen 
was approved in 2000. A bridging trial of risedronate at 35 or 
50 mg/week showed non-inferior increases of lumbar BMD 
with both regimens as compared with the 5 mg/day approved 
dosing (Brown et al 2002), resulting in 2002 approval for 
35 mg weekly oral risedronate.
Monthly oral regimens
The currently available monthly oral ibandronate regimen 
was approved in 2005 on the basis of the 2-year Monthly Oral 
IBandronate in LadiEs (MOBILE) bridging trial (Miller et al 
2005; Reginster et al 2006). In the MOBILE trial, monthly 
oral ibandronate regimens (100 or 150 mg/month) proved as 
effective as the approved daily regimen at improving lumbar 
BMD (Table 2). The 150 mg/month regimen subsequently 
showed superiority to 100 mg/month and 2.5 mg/day at 
lumbar spine and total hip BMD improvement (Miller et al 
2005; Reginster et al 2006). Signiﬁ  cantly greater percentages 
of patients achieved measurable 2-year BMD gains at lumbar 
spine, total hip, or both with the 150 mg/month regimen 
vs 2.5 mg/day (p   0.004) or 100 mg/month (p   0.01) 
(Reginster et al 2006). Additionally, 150 mg/month ibandro-
nate resulted in signiﬁ  cantly higher percentages of patients 
achieving target BMD gains ( 3% or  6%) at these sites 
(Reginster et al 2006).
An oral risedronate regimen consisting of 75 mg/day 
for 2 consecutive days monthly received US approval 
in April 2007, based on a bridging study showing its 
non-inferiority to the approved daily risedronate regimen 
(Table 2) (Delmas et al 2008a). The Monthly Evaluation of 
Risedronate Trial in OsteoPorosis (MERIT-OP) (Delmas 
et al 2008b) subsequently reported similar non-inferiority 
results for a 150 mg/month risedronate regimen approved 
in April 2008 (Table 2).
Quarterly iv regimens
Quarterly iv ibandronate received FDA approval in 2007 
on the basis of the Intermittent Regimen iv Ibandronate 
Study (IRIS) (Adami et al 2004) and Dosing IV Administra-
tion (DIVA) (Delmas et al 2006; Eisman et al 2008) trials 
(Table 2), whose lumbar BMD endpoints demonstrated non-
inferiority to the approved daily oral ibandronate regimen. 
Both iv regimens in the DIVA trial achieved lumbar BMD 
increases statistically superior to oral dosing (Table 2) 
(Delmas et al 2006; Eisman et al 2008). Efﬁ  cacy against 
non-vertebral fractures was subsequently demonstrated for 
the quarterly iv and monthly oral ibandronate regimens in 
pooled analyses (Cranney et al 2007; Harris et al 2008).
treatment, whereas from 5 years onward other sites showed 
stable or decreasing BMD (Bone et al 2004). Clinically 
evident vertebral fractures were less common than in the 
group who switched to placebo, who experienced hip and 
spine BMD declines after discontinuing alendronate (Black 
et al 2006).
Placebo-controlled trials supporting the approval of 
daily oral risedronate (5 mg/day) evaluated hip fractures 
among women with osteoporosis or non-skeletal risk factors 
(the Hip Intervention Program [HIP]) (McClung et al 2001) 
or new vertebral fractures among women with prevalent 
vertebral fractures (Vertebral Efﬁ  cacy with Risedronate 
Trial [VERT]) (Reginster et al 2000). In HIP (McClung et al 
2001), relative hip fracture risk was signiﬁ  cantly reduced 
with risedronate vs placebo in the overall patient set and 
among osteoporotic patients, but did not differ signiﬁ  cantly 
among non-osteoporotic patients with risk factors for falling 
(Table 2). Non-vertebral fracture risk, similarly, signiﬁ  cantly 
decreased with risedronate overall and in osteoporotic 
patients. In the multinational VERT study (Reginster et al 
2000), new vertebral fracture risk in risedronate recipients 
was reduced by 61% during the ﬁ  rst year and by 49% over 
3 years, whereas non-vertebral fracture risk was reduced by 
33% over 3 years (Table 2). Risedronate recipients in the 
North American VERT study (Harris et al 1999) showed 1-
year vertebral fracture risk reduction of 65%, 3-year vertebral 
fracture risk reduction of 41%, and non-vertebral fracture 
risk reduction of 40% (Table 2).
In the oral iBandronate Osteoporosis vertebral fracture 
trial in North America and Europe (BONE) (Chesnut et al 
2004), oral ibandronate given daily or intermittently to women 
with prevalent vertebral fractures signiﬁ  cantly reduced the 
relative risk of new vertebral fractures and clinical vertebral 
fractures compared with placebo (Table 2). Lumbar BMD 
signiﬁ  cantly increased and rates of height loss decreased in 
both ibandronate groups as compared with placebo (Chesnut 
et al 2004). Non-vertebral fracture risk also decreased by 69% 
in daily oral ibandronate recipients with low baseline femoral 
neck T-scores  −3.0 (Chesnut et al 2004). BONE supported 
the initial approval of daily oral ibandronate in 2005. Its verte-
bral fracture data provided the ﬁ  rst evidence for anti-fracture 
efﬁ  cacy of a non-daily oral bisphosphonate regimen.
Weekly oral regimens
In the Alendronate Once-Weekly Study (Schnitzer et al 
2000), a 70 mg oral once-weekly dose of alendronate resulted 
in statistically equivalent lumbar spine BMD gains to those 
seen with the 10 mg daily treatment or 35 mg twice-weekly Clinical Interventions in Aging 2008:3(4) 621
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Yearly iv regimen
The Health Outcomes and Reduced Incidence with Zole-
dronic Acid ONce Yearly (HORIZON) trial showed signiﬁ  -
cant reduction of vertebral, non-vertebral, and hip fractures 
with yearly iv zoledronic acid vs placebo in post-menopausal 
osteoporosis patients with or without prevalent vertebral 
fractures (Table 2) (Black et al 2007). A subsequent study, 
the HORIZON Clinical Fracture Trial (Lyles et al 2007), 
included women and men who underwent surgical repair of 
low-trauma hip fractures within 90 days before enrollment. 
Yearly zoledronic acid recipients in this high-risk popula-
tion showed relative risk reduction vs placebo of 35% in 
new clinical fractures and 28% in 2-year all-cause mortality 
(Lyles et al 2007).
Comparative trials
The Fosamax Actonel Comparison Trial (FACT) (Bonnick 
et al 2006) compared weekly oral alendronate (70 mg/week) 
and risedronate (35 mg/week) regimens in a 1-year head-to-
head study with a 1-year extension (Table 2). At all time points 
alendronate produced signiﬁ  cantly greater BMD increases 
than risedronate at the hip trochanter, lumbar spine, total 
hip, and femoral neck. Signiﬁ  cantly more alendronate than 
risedronate recipients attained measurable BMD gains (Sebba 
et al 2004; Bonnick et al 2006). Fractures were reported only 
as adverse events (AEs) in the FACT studies.
The 1-year randomized, double-blind, double-dummy 
Monthly Oral Therapy with Ibandronate for Osteoporosis 
INtervention (MOTION) trial recently demonstrated that 
monthly oral ibandronate provides similar efﬁ  cacy to weekly 
oral alendronate, as assessed by BMD improvements at the 
lumbar spine, total hip, trochanter, and femoral neck (Table 2) 
(Miller et al 2008). Fractures were reported only as AEs in 
the MOTION study.
Meta-analyses of non-vertebral fracture efﬁ  cacy
The FDA requires direct anti-fracture endpoints to approve 
new bisphosphonate agents; initial trials are often designed 
and powered for primary endpoints of vertebral fracture. 
All approval trials for currently used nitrogen-containing 
bisphosphonates except HIP (risedronate) and HORIZON 
(zoledronic acid) were designed with primary vertebral 
fracture endpoints. In contrast, regimen extensions of exist-
ing agents can be approved on the basis of bridging trials. 
Thus, no direct anti-fracture efﬁ  cacy trials exist for weekly, 
monthly, or quarterly bisphosphonates.
Non-vertebral fractures are infrequent events; their use 
as a trial endpoint requires large or high-risk populations 
and is affected by methodological variations (Miller 2008). 
Meta-analyses are thus often used to explore treatment effects 
on non-vertebral fracture risk. Daily alendronate has been 
associated in such meta-analyses with non-vertebral fracture 
risk reductions of 14%–49% (Karpf et al 1997; Cranney et al 
2002b; Boonen et al 2005), and daily risedronate with non-
vertebral fracture risk reductions of 19%–59% (Karpf et al 
1997; Cranney et al 2002a; Harrington et al 2004; Liberman 
et al 2006). No currently published meta-analyses have spe-
ciﬁ  cally examined weekly oral bisphosphonate regimens.
Meta-analyses of extended-interval ibandronate regi-
mens based on their achieved ACE have shown signiﬁ  cant 
non-vertebral fracture risk reduction. Patients receiving 
ACE  10.8 mg (ie, approved monthly oral or quarterly iv 
ibandronate regimens or an investigational bimonthly iv 
regimen) achieved relative risk reductions versus placebo of 
29.9% for all non-vertebral fractures, and 34.4% for a set of 
6 important non-vertebral fractures (clavicle, humerus, wrist, 
pelvis, hip, leg) (Harris et al 2008). Ibandronate regimens 
with ACE  10.8 mg showed 38% relative risk reduction 
for all non-vertebral fractures versus daily oral ibandronate 
(ACE 5.5 mg) (Cranney et al 2008). These meta-analyses 
provide the ﬁ  rst evidence of non-vertebral fracture efﬁ  cacy for 
any weekly, monthly, or quarterly bisphosphonate regimen.
Safety and tolerability
The most common AEs reported with bisphosphonates affect 
the upper GI (UGI) system. In part such events may reﬂ  ect 
the increased baseline incidence of UGI disorders among 
elderly patients and the synergistic effects of non-steroi-
dal anti-inﬂ  ammatory drugs (NSAIDs) used for comorbid 
arthritis. Adherence to oral dosing requirements (taking 
bisphosphonates with  8 ﬂ  uid oz (237 mL) water after 
an overnight fast and not reclining, eating, or drinking for 
30–60 minutes after dosing) reduces UGI AEs and enhances 
absorption. AEs affecting other body systems are somewhat 
less frequent.
Oral ibandronate (daily or intermittent) shows UGI 
AE frequencies similar to placebo, even among patients 
with histories of UGI disorders or concomitant anti-ulcer 
or NSAID treatment (Epstein et al 2006). Head-to-head 
studies indicate that safety and tolerability proﬁ  les, and in 
particular UGI tolerability, appear not to vary greatly among 
different oral bisphosphonates. In the FACT (Bonnick et al 
2006), overall AEs, serious AEs, and discontinuations due 
to AEs were similar between 70 mg/week alendronate and 
35 mg/week risedronate. UGI AEs (predominantly dyspepsia, 
nausea, and reﬂ  ux) affected 24.8% of alendronate recipients   Clinical Interventions in Aging 2008:3(4) 622
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and 22.9% of risedronate recipients; and 1.7% and 1.2%, 
respectively, discontinued because of UGI AEs (Bonnick 
et al 2006). In the MOTION trial (Delmas et al 2007b), the 
incidence of UGI AEs was similar between weekly oral 
alendronate (17.2%) and monthly oral ibandronate (17.5%); 
however, more alendronate users withdrew because of treat-
ment-related UGI AEs (1.7% vs 1.0% of ibandronate users). 
Because UGI AEs generally result from topical irritation, 
agents designed for less frequent oral dosing may reduce 
cumulative risk (Epstein et al 2006).
Osteonecrosis of the jaw (ONJ) is an infrequent but 
troublesome bisphosphonate-related AE thought to result 
from antiangiogenesis (Migliorati 2003; Migliorati et al 
2006), impaired circulation, or excessive osteoclast sup-
pression (Carter et al 2005). Most ONJ reports are associ-
ated with iv pamidronate or zoledronic acid prescribed for 
hypercalcemia of malignancy or skeletal metastases (indica-
tions requiring higher and more frequent doses than are used 
in osteoporosis). Cumulative worldwide ONJ reports with 
oral bisphosphonates (as of 2006) have included 170 with 
alendronate, 12 with risedronate and a single patient who had 
received both ibandronate and iv zoledronic acid (American 
Dental Association Council on Scientiﬁ  c Affairs 2006). 
A 2007 systematic review (Pazianas et al 2007) collected 26 
ONJ cases in adult osteoporosis patients receiving bisphos-
phonates (alendronate, 23; alendronate and zoledronic acid, 1; 
pamidronate, 1; risedronate, 1; ibandronate, 0). Advancing 
age, dental extractions, and corticosteroid use showed sig-
niﬁ  cant associations with ONJ risk.
Reports of atrial ﬁ  brillation in trials of yearly iv zole-
dronic acid (Black et al 2007) and daily oral alendronate 
(Cummings et al 2007) recently prompted an FDA safety 
review of this AE among bisphosphonate users (Food and 
Drug Administration 2007). Although serious atrial ﬁ  brilla-
tion events in these studies (Black et al 2007; Cummings et al 
2007) were signiﬁ  cantly more frequent in drug recipients, 
no signiﬁ  cant difference was seen between bisphosphonates 
and placebo when all atrial ﬁ  brillation events were consid-
ered. Neither serious nor overall atrial ﬁ  brillation events 
signiﬁ  cantly differed between zoledronic acid and placebo 
in the HORIZON Recurrent Fracture trial, which enrolled 
an older patient population than the pivotal HORIZON 
study (Lyles et al 2007). Postdose electrolyte imbalances 
(hypocalcemia, hypophosphatemia, or hypomagnesemia) 
have been suggested to be responsible for atrial ﬁ  brillation 
during bisphosphonate use (de Nijs and Westgeest 2007; 
Poole et al 2007); however, the causality of this AE is not 
known with certainty. An October 2007 early communication 
about the ongoing safety review stated that bisphosphonate 
prescribing patterns need not change at this time (Food and 
Drug Administration 2007).
Reduced kidney function has been reported in 9% to 
15% of patients receiving iv zoledronic acid or pamidronate 
(Chang et al 2003). In the HORIZON trial (Black et al 2007), 
increases of serum creatinine  0.5 g/dL occurred at 9–11 days 
postdose in signiﬁ  cantly more zoledronic acid recipients (iv 
5 mg/year) than placebo recipients (1.2% vs 0.4%, p = 0.001). 
In 85% of cases, levels reverted in 30 days to within 0.5 g/dL 
of baseline, and by the third year of the study, there was no 
signiﬁ  cant difference between study groups. Although iv 
ibandronate labeling includes a precaution regarding hypo-
calcemia and renal impairment, iv ibandronate has shown no 
evidence of affecting renal function in patients with cancer-
related bone disease (Strampel et al 2007) or in DIVA trial 
participants (Rizzoli and Reid 2007). In a pooled analysis 
of 4 trials comprising 6815 patients with osteoporosis and 
estimated glomerular ﬁ  ltration rates  30 mL/min/1.73 m2, 
changes in estimated creatinine clearance throughout study 
duration were modest and similar among iv ibandronate, daily 
oral ibandronate, and placebo groups (Miller et al 2007). 
Patients receiving iv bisphosphonate medications should have 
their serum creatinine measured regularly.
Ocular inﬂ  ammatory AEs (conjunctivitis, episcleritis, 
uveitis, or scleritis) are occasionally associated with nitrogen-
containing bisphosphonates (particularly with regimens used 
in cancer) and may be mediated by tumor necrosis factor-α 
and interleukins 1 and 6 (Fraunfelder 2003; Fraunfelder 
2007). Patients experiencing eye pain during bisphospho-
nate use require immediate referral to an ophthalmologist. 
Conjunctivitis and episcleritis may be treated topically; 
uveitis and scleritis require bisphosphonate discontinuation 
(Fraunfelder 2003; Fraunfelder 2007).
A transient ﬂ  u-like illness (fever, myalgia, arthralgia, and 
malaise) may occur upon initial bisphosphonate use (espe-
cially with iv use or the oral dose levels used in monthly or 
intermittent treatment) and is thought to represent an acute 
phase reaction to accumulated by-products of prenylation 
inhibition (Bukowski et al 2005). Generally, symptoms are 
mild, last only 1–3 days, and diminish in incidence and sever-
ity with subsequent doses.
Patient perspectives: improving 
treatment uptake, adherence, 
and persistence
Osteoporosis prevention is a lifelong endeavor, and 
osteoporosis treatment ideally starts at or before the initial Clinical Interventions in Aging 2008:3(4) 623
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BMD decline after menopause. Care of elderly patients 
presenting with incident fractures must go beyond emergent 
repair to assessment and reduction of recurrent fracture risk. 
In one Midwestern community care system, process improve-
ments utilizing follow-up of orthopedic billings provided 
osteoporosis evaluation and treatment to 58% of incident 
fragility fracture patients in 2003, in contrast to only 5% 
in 1999 (Harrington et al 2005). Patients with incident hip 
or spine fractures face increased future fracture risk (Black 
et al 1999; Lindsay et al 2001) as well as acute risk of dis-
ability and mortality. Treating underlying osteoporosis in 
such patients may conserve medical and ﬁ  nancial resources, 
functional capacity, and life expectancy.
The achievement and maintenance of fracture preven-
tion beneﬁ  ts requires continuity of osteoporosis treatment. 
Unfortunately, adherence and persistence with treatment 
are problematic in all chronic diseases and pose particular 
challenges in osteoporosis. Oral bisphosphonate dosing 
requirements are inconvenient for patients; thus, less frequent 
treatment intervals are conducive to better patient acceptance, 
adherence, and persistence. The US Surgeon General’s Report 
on Bone Health and Osteoporosis (US Department of Health 
and Human Services 2004) has highlighted the need for 
interventions that improve adherence and for research speciﬁ  -
cally exploring the impact of dosing regimens on adherence. 
By making therapy less intrusive to daily life, oral regimens 
with less frequent dosing may provide improved real-world 
effectiveness.
Patient preferences and adherence: 
obstacles and opportunities
Patient inconvenience in osteoporosis treatment is not just a 
nuisance but a real hazard to effective clinical outcomes, as 
disruption of maintenance regimens can have severe physical 
consequences. Premature discontinuation of bisphosphonate 
therapy has been associated with up to 26% increase in 
fracture risk (Chesnut 2006; Gold et al 2007), and frequent 
oral dosing strongly predicts earlier discontinuation (Cramer 
et al 2005). Adherence and persistence with bisphospho-
nate therapy are important not only for direct anti-fracture 
beneﬁ  ts, but also for reduced overall healthcare require-
ments. In a retrospective study of 32,944 women initiating 
bisphosphonate treatment, those remaining adherent and 
persistent had signiﬁ  cantly lower total healthcare costs than 
those with gaps or discontinuation of therapy (Curtis et al 
2006). Adherence to weekly dosing is improved over daily 
regimens (Cramer et al 2005; Gold et al 2007), but remains 
suboptimal. Only 45% of weekly bisphosphonate recipients 
in a large longitudinal study maintained adherence and only 
57% maintained persistence over 1 year (Chesnut 2006). 
Thus, though once-weekly therapy represents a move toward 
a more patient-friendly regimen, it still presents obstacles to 
sustained treatment.
Once-monthly oral ibandronate may reduce the cumula-
tive inconvenience of an oral bisphosphonate regimen and 
help patients maintain continuity of treatment. Once-monthly 
ibandronate users in 2 recent retrospective database studies 
(N = 17,479 and N = 11,664) were respectively 25.1% and 
37.7% less likely than once-weekly oral bisphosphonate 
users to discontinue therapy before 1 year (Silverman et al 
2007b). The naturalistic PERsistence Study of Ibandronate 
verSus alendronaTe (PERSIST) study in the UK (Cooper 
et al 2006) compared persistence times among women in 
primary care randomized to 6 months of open-label treatment 
with monthly oral ibandronate or weekly oral alendronate. 
Ibandronate recipients were offered a patient support program 
(PSP) available to all UK patients prescribed ibandronate; 
no similar program existed at the time of the study for alen-
dronate users in the community. Kaplan–Meier analysis 
showed a signiﬁ  cantly higher probability of persistence in 
the ibandronate/PSP group (p   0.0001); mean (± SD) per-
sistence times were 122 ± 2.5 days for ibandronate/PSP and 
109 ± 2.5 days for alendronate (Cooper et al 2006). How-
ever, conﬂ  icting results are reported in different persistence 
comparisons (Weiss et al 2007). Once-monthly ibandronate 
was preferred over once-weekly alendronate by 66.1% of 
patients in the randomized, crossover Boniva Alendronate 
Trial in Osteoporosis (Emkey et al 2005).
Patients who cannot tolerate or do not prefer oral dosing 
may opt for quarterly iv ibandronate injection (Rizzoli and 
Reid 2007) or yearly iv zoledronic acid infusion (Black et al 
2007). These regimens abrogate oral dosing requirements, 
but require periodic visits to a physician’s ofﬁ  ce or infu-
sion center for administration. Outpatients with adverse GI 
histories on daily or weekly oral bisphosphonates achieved 
improved adherence to quarterly iv ibandronate (Lewiecki 
et al 2008). Yearly iv zoledronic acid has been preferred 
by a majority of trial outpatients who switched to it from 
weekly oral alendronate (McClung et al 2007; Saag et al 
2007). Intravenous regimens may be particularly advanta-
geous for elderly patients residing in long-term care facilities 
or those with impairments affecting medication self-man-
agement. The availability of multiple oral and iv options 
gives patients the opportunity to decide which attributes of 
a bisphosphonate regimen they consider most important for 
long-term sustainability.Clinical Interventions in Aging 2008:3(4) 624
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Physiologic assessments of adherence 
and response
The clinical silence of osteoporosis until fractures occur 
may create challenges in sustaining patients’ motivation 
for treatment. BMD change is clinically measured no more 
often than every 2 years (Bonnick and Shulman 2006). 
Earlier demonstration of therapeutic response may help to 
motivate patients and to detect non-adherence. Biomarkers 
of bone turnover (Table 2), measured in serum or urine, 
change much more rapidly than BMD (Bonnick and Shul-
man 2006), and thus may provide early objective feedback 
on adherence and response. Decreased CTX at various time 
points during bisphosphonate therapy is strongly correlated 
with BMD increases at 6 months and 1 year (Leeming et al 
2006). Conversely, high CTX levels may predict fracture 
risk; in the Epidemiology of Osteoporosis study (Garnero 
et al 1996a), elderly women with elevated urinary CTX had 
a 4.8-fold increased risk of hip fractures.
Patients’ responses to biomarker-based feedback showed 
unexpected patterns in a 1-year prospective study of risedro-
nate treatment (5 mg/day orally for 1 year) with and without 
a reinforcement program (urinary NTX testing and patient 
education at weeks 13 and 25) (Delmas et al 2007a). In addi-
tion to the biomarker follow-up, persistence was measured 
directly with electronically monitored pill dispensers; overall 
persistence over 1 year was 77% in the reinforcement group 
and 80% in the non-reinforcement group. Counterintuitively, 
patients who were informed of a poor NTX response ( 30% 
increase, indicating poor adherence) were roughly twice as 
likely to discontinue therapy prematurely. In contrast, patients 
informed of a good NTX response ( 30% decrease) showed 
improved persistence rates after the reinforcement visit 
(Delmas et al 2007a). Patients in the reinforcement group had 
less than half the incidence of new vertebral fractures as in the 
non-reinforcement group. Interventions that increase persis-
tence with bisphosphonates improve fracture protection.
Recent developments thus allow a multipronged approach 
to maintaining the continuity of bisphosphonate treatment. 
Monthly or less frequent regimens lessen lifestyle disrup-
tion, preference assessments identify the attributes patients 
value, and bone turnover markers provide physiologic 
accountability.
Conclusions
Nitrogen-containing bisphosphonates have become the stan-
dard of care for postmenopausal osteoporosis, in company 
with calcium and vitamin D supplementation and weight-
bearing physical activity. Oral bisphosphonate dosing requires 
stringent dosing guidelines to maximize bioavailability 
and minimize UGI irritation. The inconvenience this poses 
to patients has motivated the development of weekly and 
monthly oral regimens to enhance adherence, as well as quar-
terly and yearly iv regimens for patients unable to tolerate 
oral dosing. Ibandronate is the ﬁ  rst bisphosphonate to have 
shown direct anti-fracture efﬁ  cacy with a non-daily regimen; 
it was approved for once-monthly oral dosing in 2005 and 
for quarterly iv dosing in 2006. Yearly iv zoledronic acid was 
approved in 2007; it has shown improvement of fracture rates 
and post-fracture mortality, although the recent FDA early 
communication about atrial ﬁ  brillation and bisphosphonate 
use certainly warrants ongoing safety review. The availability 
of once-monthly and less frequent bisphosphonate regimens 
promises to improve patient satisfaction and adherence, and 
thus to increase the real-world effectiveness of osteoporosis 
therapy.
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